Mesoblast Board Changes
Key Highlights
- ➤William Burns to retire from Mesoblast’s Board after 12 years at 2026 Annual General Meeting
- ➤Philip Krause to retire after serving as a Mesoblast director since 2022
- ➤Mesoblast plans new directors with U.S. and global commercial biotechnology expertise
- ➤Mesoblast is now revenue-generating following RYONCIL’s successful United States launch
Expert Statements
Philip Facchina, Chair of Mesoblast
“On behalf of the Board, I wish to thank Mr Burns for his broad contributions spanning more than a decade and Dr Krause for his significant contribution to Mesoblast as a director. The Company is now a revenue-generating commercial enterprise following the successful launch of RYONCIL in the United States. In line with this, we plan to recruit and appoint new directors with U.S. and global commercial expertise in the biotechnology and pharmaceutical sectors.”
NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth.
After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at the Company’s 2026 Annual General Meeting. Ms Jane Bell AM will take over as Chair of the Nomination and Remuneration Committee, having been co-Chair with Mr Burns since April 2026. The Board recognizes the contribution by Mr Burns to the Company’s strategic direction and corporate governance.
Get started
Create a free account to read the full story.